New pill aims to tackle high blood pressure and weight together

NCT ID NCT07360275

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called VCT220 in 160 adults with high blood pressure who are also overweight or obese. Participants will take either VCT220 or a placebo pill for 20 weeks. The main goal is to see if VCT220 can safely lower blood pressure more than a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

VCT220 tablet

What this could lead to

If successful, this could point toward a new treatment option for people with high blood pressure who are also overweight or obese.

What could go wrong

This is an early Phase 2 trial with only 160 participants, so results may not apply to everyone. The drug may not work better than placebo or could have side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Luhe Hospital

    Beijing, Beijing Municipality, 100044, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Peking University People's Hospital

    Beijing, Beijing Municipality, 100044, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••